Results 211 to 220 of about 33,878 (223)

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

New England Journal of Medicine, 2013
Denis Fouque, Bruno Moulin, Giuseppe Remuzzi   +2 more
exaly  

Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update

Toxins, 2018
Raymond C Vanholder, Eva Schepers, Griet Glorieux   +2 more
exaly  

Neonatal Hemolytic-Uremic Syndrome

Clinical Pediatrics, 1995
J, Figueras, A, Roldán, F, Botet, A, Palacin, R, Jiménez   +4 more
openaire   +2 more sources

Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins

Clinical Science, 2018
Wei Ling Lau, Javad Savoj
exaly  

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial

American Journal of Kidney Diseases, 2016
Fadi Fakhouri, Josep M Campistol, Spero R Cataland   +2 more
exaly  

The Hemolytic–Uremic Syndrome

New England Journal of Medicine, 2002
Philippe, Debourdeau, Christine, Zammit, Sylvain, Guérard   +2 more
openaire   +2 more sources

Uremic toxins originating from colonic microbial metabolism

Kidney International, 2009
Pieter Evenepoel, Björn Meijers, Bert Rm Bammens   +2 more
exaly  

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome

Kidney International, 2016
Larry A Greenbaum, Gianluigi Ardissino, Lars Pape   +2 more
exaly  

Treatment of Uremic Pruritus: A Systematic Review

American Journal of Kidney Diseases, 2017
Paul Komenda, Blake Lerner, Nicole Askin
exaly  

Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation

Kidney International, 2012
Chiao-Yin Sun, Shih-Chung Chang
exaly